Letermovir for Cytomegalovirus Prevention in Adolescent Patients Following Hematopoietic Cell Transplantation
Nicole P. Daukshus, Anthony Cirincione, Molly Siver, Sherry Mathew, Binni Kunvarjee, Amelia Chan, Jaap Jan Boelens, Susan K. Seo, Genovefa A. Papanicolaou, Nancy A. Kernan
Abstract
There are limited data for letermovir as primary cytomegalovirus (CMV) prophylaxis in patients less than 18 years of age. We report 9 adolescent patients who received letermovir following hematopoietic cell transplantation. No patients developed clinically significant CMV while taking letermovir. Letermovir was well tolerated and efficacious in preventing CMV infections.
Topics & Concepts
MedicineHematopoietic cellCytomegalovirusHematopoietic stem cell transplantationTransplantationBone marrow transplantationImmunologyHaematopoiesisInternal medicineHuman immunodeficiency virus (HIV)HerpesviridaeViral diseaseStem cellBiologyGeneticsCytomegalovirus and herpesvirus researchHerpesvirus Infections and TreatmentsToxoplasma gondii Research Studies